Cefazolin is named as an intervention in 7 current clinical trials in our Canada, Australia, Germany, France, Netherlands, Sweden, Japan, Singapore, Israel, Belgium and South Korea registers. 6 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is University of Melbourne (1). The most-studied condition is Staphylococcus Aureus Bacteremia. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Cefazolin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
|
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis
2025-521988-13-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 4 | Authorised | Assistance Publique Hopitaux De Paris | France |
| Condition (as registered) | Trials |
|---|---|
| Staphylococcus Aureus Bacteremia | 1 |
| Paracetamol | 1 |
| Cefazolin | 1 |
| Orthognathic Surgical Site Infection | 1 |
| Propionibacterium Infection | 1 |
| Surgical Site Infection | 1 |
| Pancreatoduodenectomy | 1 |
| PPPD | 1 |
| Infectious Complications | 1 |
| Bone Infection | 1 |
| Septic Arthritis | 1 |
| Bone and Joint Infection | 1 |
| Osteomyelitis | 1 |
| Lead sponsor | Trials |
|---|---|
| University of Melbourne | 1 |
| University Hospital, Ghent | 1 |
| Abdul El-Rabbany | 1 |
| Université de Montréal | 1 |
| Monash University | 1 |
| Asan Medical Center | 1 |
| Murdoch Childrens Research Institute | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
7 current trials in our Canada, Australia, Germany, France, Netherlands, Sweden, Japan, Singapore, Israel, Belgium and South Korea registers name Cefazolin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 7 trials are recruiting: 4 with sites in Canada, 3 with sites in Australia, 1 with sites in Germany, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Sweden, 1 with sites in Japan, 1 with sites in Singapore, 1 with sites in Israel and 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University of Melbourne (1), University Hospital, Ghent (1), Abdul El-Rabbany (1) and Université de Montréal (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cefazolin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cefazolin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cefazolin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.